GLUE (Monte Rosa Therapeutics) Earnings growth in current year

Protected by a patented IT platform, Monte Rosa Therapeutics (GLUE) is navigating rigorous FDA oversight. The year-over-year change in EPS illustrates capital dynamics, where the -128.80 mark reflects the latest data. Profit prospects depend on insurance payouts for "molecular glues," although the current trial phase is accompanied by a full burn rate of funds prior to the confirmation of therapy efficacy.

GLUE (Monte Rosa Therapeutics, Inc.) Earnings growth in current year history from 07/04/2022 to 11/10/2026

Comprehensive metric breakdowns and analytics for Monte Rosa Therapeutics (GLUE)

- share price and expert price forecast:

Price Monte Rosa Therapeutics Inc|GLUE - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Monte Rosa Corp|GLUE - Total Company Value

- book capitalization data:

Accounting Value of a Share Monte Rosa Therapeutics|GLUE - Book Capitalization|Market Value to Equity Ratio monterosatx.com|GLUE - Company Total Assets

- debt and liquidity details:

- net income and valuation multiples indicators:

GLUE - Net Income|Future Net Profit Monte Rosa Therapeutics|GLUE - P/E Multiple|Future Price to Earnings Multiple Monte Rosa Corp|GLUE - PEG Multiple|Company Value to EBITDA Monte Rosa Corp|GLUE - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Monte Rosa Therapeutics|GLUE - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth monterosatx.com|GLUE - Earnings per share growth in current year|Net earnings per share change forecast for next year Monte Rosa Therapeutics

Fundamental valuation:GLUE Monte Rosa Therapeutics Inc

This indicator measures the year-over-year dynamics of net earnings per share, stripping out one-time write-offs from the financial result to identify the actual stability of capital. By analyzing the year-over-year change in earnings per share, an investor assesses the capitalization efficiency of Monte Rosa Therapeutics (GLUE), whose innovations in molecular glues and partnerships with pharma behemoths are converting into institutional growth.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Corp) - Earnings growth in current year|Earnings growth in current year Nuvalent Therapeutics|Earnings per share growth in current year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics, Inc.)|Net earnings per share change in current year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth in current year|Earnings per share growth rate in current year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Net earnings per share growth this year|VSTM: Net earnings per one share growth for the current year|CGEM (Cullinan Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Immuneering Corp IMRX|Earnings growth in current year CCCC|Black Diamond Therapeutics, Inc - Earnings per share growth this year|Repare Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year PMVP|KPTI: Net earnings per share growth this year|Propanc Biopharma Inc - Net earnings per one share growth for the current year|BGMS: Earnings growth in current year|Aadi Bioscience, Inc. - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year Blueprint Medicines Corp BPMC|Earnings per share growth in current year GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year